Title: Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
Authors: San Miguel, Jesus F
Schlag, Rudolf
Khuageva, Nuriet K
Dimopoulos, Meletios Athanasios
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T
Palumbo, Antonio
Samoilova, Olga S
Dmoszynska, Anna
Abdulkadyrov, Kudrat M
Delforge, Michel
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C
Esseltine, Dixie-Lee
Liu, Kevin
Deraedt, William M
Cakana, Andrew Z
van de Velde, Helgi
Richardson, Paul G #
Issue Date: Nov-2011
Publisher: Amer soc hematology
Host Document: Blood vol:118 issue:21 pages:221-222
Conference: 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) San Diego, CA, DEC 10-13, 2011
ISSN: 0006-4971
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Embryo and Stemcells (-)
# (joint) last author

Files in This Item:

There are no files associated with this item.


All items in Lirias are protected by copyright, with all rights reserved.